News
CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...
The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per ...
CVS Health plans to exit the individual Obamacare health insurance business next year, leaving 1 million people in 17 states ...
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...
CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...
CVS and Novo Nordisk have struck a deal that will see the drugstore chain offering the Wegovy weight-loss drug to customers ...
Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...
Parade Pets on MSN1d
Great Pyrenees Patiently Waiting for Treat at CVS Pharmacy Is the Ideal CustomerThe proof is in the video below, where a Great Pyrenees named Ritchie formed a bond with a total stranger who showed him such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback